

INDEX

ABSTRACT	11
INTRODUCTION	25
Antibiotic resistance and tuberculosis	23
Mechanisms and evolution of drug resistance in <i>M. tuberculosis</i>	29
Genomics and drug resistance detection in tuberculosis	33
Tuberculosis comorbidities and TB-HIV coinfection	37
OBJECTIVES OF THIS DISSERTATION	43
CHAPTER 1	49
An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in <i>Mycobacterium tuberculosis</i>	
INTRODUCTION	51
METHODS	55
Strains, media and culture conditions	55
Mutant pool generation and selection experiment	55
DNA extraction	56
Library preparation and sequencing	57
Bioinformatic analysis	58
Clinical dataset phylogeny and ancestral state reconstruction	61
Phylogenetic association test	62
Resistance prediction in the clinical dataset	64
Candidates validation using BCG mutants	65
Statistics and Reproducibility	66
RESULTS	67
Functional genomics allows for detection of resistance-associated genomic regions	67
Genes associated with altered resistance follow definite functional patterns	73
A phylogenetic association test identifies candidate regions associated with clinical resistance	76
Novel isoniazid resistance determinants were identified by combining functional genomics and phylogenetic association	77
Novel isoniazid resistance determinants explain resistance in phenotypically resistant strains with no known mutation	85
DISCUSSION	88
CHAPTER 2	93
Genomic analyses of <i>Mycobacterium tuberculosis</i> from human lung resections reveal a high frequency of polyclonal infections	
INTRODUCTION	95
METHODS	100
Sampling	100

Culture and drug susceptibility testing	102
DNA extraction and sequencing	102
Bioinformatic analysis	103
Phylogenetic and population genetics analyses	105
Prediction of WGS-DST profiles and comparison with culture DST	106
Identification of polyclonal infections	106
RESULTS	111
A high frequency of polyclonal infections in MDR-TB patients from Georgia	111
TB patients undergoing lung surgery show complex infection scenarios	117
Patient follow-up treatment can be compromised by polyclonal infection	120
Diversity within and around lesions reflects host microenvironment pressures	123
DISCUSSION	127
CHAPTER 3	133
HIV coinfection impacts <i>Mycobacterium tuberculosis</i> diversity and drug resistance acquisition during early treatment	
INTRODUCTION	135
METHODS	138
Cohort recruitment and sampling	138
Culture and MIC determinations	138
DNA extraction and sequencing	139
Bioinformatic analysis	140
Prediction of drug resistance profiles and comparison with MIC determinations	141
RESULTS	143
HIV affects TB within-patient diversity and the ability to reduce it	144
Heteroresistance is generated at low frequencies under treatment selective pressure	146
MIC shifts as early markers of treatment failure	149
DISCUSSION	164
GENERAL DISCUSSION	171
CONCLUSIONS	193
SUPPLEMENTARY INFORMATION	199
REFERENCES	217